Detalhe da pesquisa
1.
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.
Br J Haematol
; 2024 May 08.
Artigo
Inglês
| MEDLINE | ID: mdl-38719214
2.
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.
Haematologica
; 2024 Apr 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38572568
3.
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Haematologica
; 108(4): 958-968, 2023 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36263838
4.
Venetoclax salvage therapy in relapsed/refractory multiple myeloma.
Haematologica
; 109(3): 979-981, 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37794827
5.
Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1.
Biomark Res
; 11(1): 52, 2023 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37194045
6.
Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.
Commun Biol
; 6(1): 1299, 2023 12 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38129580